Ensem Therapeutics doses first patient in phase 1/2 clinical study of ETX-636, a novel allosteric pan-mutant-selective PI3Ka inhibitor and degrader

Ensem Therapeutics, Inc, a pioneering drug discovery and development company to leverage its unique kinetic ensemble platform to advance innovative small molecule precision medicines for oncology, announced

To access the full article, please log in or subscribe.